22 February, 2016 - Stallergenes Greer plc (the 'Company'), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced its financial calendar for the year 2016:
FY 2015 Results | 27 April 2016 |
Investor and Analyst Call | 28 April 2016 |
Annual Report Filing | 29 April 2016 |
Annual General Meeting | 9 June 2016 |
1 semester 2016 Results | 25 August 2016 |
Strategy and R&D Day | November 2016 |
Please note that Stallergenes Greer will release its financial results for the year 2015 the 27 of April after market close. Fereydoun Firouz, Chief Executive Officer, and Peter Bühler, Chief Financial Officer, will host the investor and analyst call on the 28 of April at 2:00 pm (CET).
The Company's Annual General Meeting will be held on the 9 of June in Paris, France. Stallergenes Greer will hold a Strategy and R&D Day in Antony, France in November 2016.
ABOUT STALLERGENES GREER PLC
Headquartered in London (UK), Stallergenes Greer plc is a global company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).
Trading information:
Name: Stallergenes Greer
ISIN: GB00BZ21RF93 1 - Ticker: STAGR
ICB classification: 4577
Market: Euronext Paris regulated market
Contacts:
Investor and analyst relations
Peter Bühler
Chief Financial Officer
Tel: +33 (0)1 55 59 23 22
Email: investorrelations@aresallergyco.com
Investor and Media relations agency
Robin Wrench / Agnes Catineau
Brunswick Group
Tel: +44 (0)20 7404 5959
Email: stallergenesgreer@brunswickgroup.com
Media relations
Lise Lemonnier
Head of Global Communications
Tel: + 33 (0)1 55 59 20 96
Email: llemonnier@stallergenes.com
Download PDF Press Release
This document (including information incorporated by reference in this document), oral statements made and other information published by the company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the company. These statements can be identified by the use of forward-looking terminology such as 'believe', 'expects', 'project', 'estimated', 'forecast', 'should', 'plan', 'may' or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in our prospectus filed with the French Autorité des marchés financiers on September 3, 2015. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.
Stallergènes SA issued this content on 22 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 22 February 2016 18:11:16 UTC
Original Document: http://stallergenesgreer.com/stallergenes-greer-announces-its-2016-financial-calendar/